CN1236781A - 他唑巴坦半水合物的制备与应用 - Google Patents
他唑巴坦半水合物的制备与应用 Download PDFInfo
- Publication number
- CN1236781A CN1236781A CN 99100092 CN99100092A CN1236781A CN 1236781 A CN1236781 A CN 1236781A CN 99100092 CN99100092 CN 99100092 CN 99100092 A CN99100092 A CN 99100092A CN 1236781 A CN1236781 A CN 1236781A
- Authority
- CN
- China
- Prior art keywords
- tazobactam
- preparation
- semihydrate
- sodium
- light yellow
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
C | H | N | S | |
理论值实验值 | 38.8738.70 | 4.244.12 | 18.1218.10 | 10.3510.42 |
批号 | 961111 | 961112 | 961113 | 961114 |
费休氏法(%) | 2.94 | 2.96 | 2.99 | 3.00 |
60℃真空干烤法(%) | 0.01 | 0.05 | 0.07 | 0.06 |
Δ(费休氏法-干烤法) | 2.93 | 2.91 | 2.92 | 2.94 |
TGA法(%) | 0.03 | 0.07 | 0.05 | 0.08 |
Δ(费休氏法-TGA法) | 2.91 | 2.89 | 2.94 | 2.92 |
批号 | 引湿增重百分数(%) | 结果判断 |
9610191 | 0.15 | 无引湿性 |
9610192 | 0.21 | 无引湿性 |
9610193 | 0.13 | 无引湿性 |
时间 | 批号 | 外观 | 水分(%) | 主组分(%) | 降解产物(%) |
0天 | 96101919610192 | 白色略带浅黄色白色略带浅黄色 | 3.02.9 | 100.0(93.2)100.0(95.8) | 4.452.40 |
1天 | 96101919610192 | 白色略带浅黄色白色略带浅黄色 | 3.02.9 | 100.1(93.3)99.9(95.7) | 4.312.43 |
3天 | 96101919610192 | 白色略带浅黄色白色略带浅黄色 | 3.03.0 | 99.8(93.0)99.2(95.0) | 4.442.39 |
5天 | 96101919610192 | 白色略带浅黄色白色略带浅黄色 | 3.02.9 | 100.3(93.5)100.1(95.9) | 4.522.47 |
10天 | 96101919610192 | 白色略带浅黄色白色略带浅黄色 | 3.03.0 | 100.4(93.6)99.7(95.5) | 4.332.41 |
时间 | 批号 | 外观 | 水分(%) | 主组分(%) | 降解产物(%) |
0天 | 96101919610192 | 白色略带浅黄色白色略带浅黄色 | 3.02.9 | 100.0(93.2)100.0(95.8) | 4.452.40 |
1天 | 96101919610192 | 白色略带浅黄色白色略带浅黄色 | 3.03.0 | 99.6(92.8)100.1(95.9) | 4.362.45 |
3天 | 96101919610192 | 白色略带浅黄色白色略带浅黄色 | 3.03.1 | 99.7(92.9)100(95.8) | 4.392.37 |
5天 | 96101919610192 | 白色略带浅黄色白色略带浅黄色 | 3.13.1 | 99.9(93.1)100(95.8) | 4.402.47 |
10天 | 96101919610192 | 白色略带浅黄色白色略带浅黄色 | 3.23.3 | 99.7(92.9)99.9(95.7) | 4.512.42 |
时间 | 批号 | 外观 | 水分(%) | 主组分(%) | 降解产物(%) |
0天 | 96101919610192 | 白色略带浅黄色白色略带浅黄色 | 3.02.9 | 100.0(93.2)100.0(95.8) | 4.452.40 |
1天 | 96101919610192 | 白色略带浅黄色白色略带浅黄色 | 3.03.0 | 99.6(92.8)100.2(96.0) | 4.402.35 |
3天 | 96101919610192 | 白色略带浅黄色白色略带浅黄色 | 3.23.1 | 100.3(93.5)100.5(96.3) | 4.492.47 |
5天 | 96101919610192 | 白色略带浅黄色白色略带浅黄色 | 3.23.1 | 99.7(92.9)100.4(96.2) | 4.482.41 |
10天 | 96101919610192 | 白色略带浅黄色白色略带浅黄色 | 3.23.2 | 100.2(93.4)100.1(95.9) | 4.412.39 |
时间 | 批号 | 外观 | 水分(%) | 主组分(%) | 降解产物(%) |
0天 | 96101919610192 | 白色略带浅黄色白色略带浅黄色 | 3.02.9 | 100.0(93.2)100.0(95.8) | 4.452.40 |
1天 | 96101919610192 | 白色略带浅黄色白色略带浅黄色 | 2.92.9 | 99.6(92.8)100.1(95.9) | 4.372.43 |
3天 | 96101919610192 | 白色略带浅黄色白色略带浅黄色 | 3.02.9 | 99.6(92.8)99.8(95.6) | 4.492.30 |
5天 | 96101919610192 | 白色略带浅黄色白色略带浅黄色 | 3.02.9 | 100.9(94.0)100.2(96.0) | 4.422.47 |
10天 | 96101919610192 | 白色略带浅黄色白色略带浅黄色 | 2.92.9 | 99.8(93.0)99.9(95.7) | 4.532.42 |
时间 | 批号 | 外观 | 水分(%) | 主组分(%) | 降解产物(%) |
0月 | 96101919610192 | 白色略带浅黄色白色略带浅黄色 | 3.02.9 | 100.0(93.2)100.0(95.8) | 4.452.40 |
1月 | 96101919610192 | 白色略带浅黄色白色略带浅黄色 | 3.03.0 | 100(93.2)99.8(95.6) | 4.522.33 |
2月 | 96101919610192 | 白色略带浅黄色白色略带浅黄色 | 2.92.9 | 99.4(92.6)100.4(96.2) | 4.672.51 |
3月 | 96101919610192 | 白色略带浅黄色白色略带浅黄色 | 2.92.9 | 99.6(92.8)99.9(95.7) | 4.342.38 |
时间 | 批号 | 外观 | 水分(%) | 主组分(%) | 降解产物(%) |
0月 | 96101919610192 | 白色略带浅黄色白色略带浅黄色 | 3.02.9 | 100.0(93.2)100.0(95.8) | 4.452.40 |
3月 | 96101919610192 | 白色略带浅黄色白色略带浅黄色 | 3.03.0 | 100(93.2)99.8(95.6) | 4.522.33 |
6月 | 96101919610192 | 白色略带浅黄色白色略带浅黄色 | 2.93.0 | 99.2(92.5)100.1(95.9) | 4.672.51 |
12月 | 96101919610192 | 白色略带浅黄色白色略带浅黄色 | 3.13.2 | 98.9(92.2)100.0(95.8) | 4.342.38 |
18月 | 96101919610192 | 白色略带浅黄色白色略带浅黄色 | 3.23.1 | 98.7(92.0)99.5(95.3) | 4.462.41 |
22月 | 96101919610192 | 白色略带浅黄色白色略带浅黄色 | 3.23.2 | 98.5(91.8)99.1(94.9) | 4.582.49 |
药物 | 抑制率(%) |
哌拉西林/他唑巴坦 | 90.24 |
头孢哌酮/舒巴坦 | 86.29 |
阿莫西林/舒巴坦 | 67.69 |
哌拉西林 | 79.15 |
他唑巴坦 | 3.38 |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN99100092A CN1109688C (zh) | 1999-01-12 | 1999-01-12 | 他唑巴坦半水合物的制备与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN99100092A CN1109688C (zh) | 1999-01-12 | 1999-01-12 | 他唑巴坦半水合物的制备与应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1236781A true CN1236781A (zh) | 1999-12-01 |
CN1109688C CN1109688C (zh) | 2003-05-28 |
Family
ID=5269787
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN99100092A Expired - Lifetime CN1109688C (zh) | 1999-01-12 | 1999-01-12 | 他唑巴坦半水合物的制备与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1109688C (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002092605A1 (fr) * | 2001-05-14 | 2002-11-21 | Otsuka Chemical Co., Ltd. | Cristal d'hydrate de compose de $g(b)-lactame |
WO2003042215A1 (en) * | 2001-11-16 | 2003-05-22 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline imipenem |
EP2595628A1 (en) * | 2010-07-19 | 2013-05-29 | Bayer HealthCare LLC | Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
WO2014052799A1 (en) | 2012-09-27 | 2014-04-03 | Cubist Pharmaceuticals, Inc. | Tazobactam arginine antibiotic compositions |
US9320740B2 (en) | 2013-03-15 | 2016-04-26 | Merck Sharp & Dohme Corp. | Ceftolozane-tazobactam pharmaceutical compositions |
US10376496B2 (en) | 2013-09-09 | 2019-08-13 | Merck, Sharp & Dohme Corp. | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4562073A (en) * | 1982-12-24 | 1985-12-31 | Taiho Pharmaceutical Company Limited | Penicillin derivatives |
GB8518422D0 (en) * | 1985-07-22 | 1985-08-29 | Beecham Group Plc | Compounds |
-
1999
- 1999-01-12 CN CN99100092A patent/CN1109688C/zh not_active Expired - Lifetime
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002092605A1 (fr) * | 2001-05-14 | 2002-11-21 | Otsuka Chemical Co., Ltd. | Cristal d'hydrate de compose de $g(b)-lactame |
WO2003042215A1 (en) * | 2001-11-16 | 2003-05-22 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline imipenem |
US7332600B2 (en) | 2001-11-16 | 2008-02-19 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline imipenem |
EP2595628A1 (en) * | 2010-07-19 | 2013-05-29 | Bayer HealthCare LLC | Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
RU2671485C2 (ru) * | 2012-09-27 | 2018-11-01 | Мерк Шарп И Доум Корп. | Антибиотические композиции тазобактама аргинина |
CN105025901A (zh) * | 2012-09-27 | 2015-11-04 | 丘比斯特药物股份有限公司 | 他唑巴坦精氨酸抗生素组合物 |
EP2900244A4 (en) * | 2012-09-27 | 2016-05-04 | Merck Sharp & Dohme | ANTIBIOTIC COMPOSITIONS FROM TAZOBACTAM ARGININE |
WO2014052799A1 (en) | 2012-09-27 | 2014-04-03 | Cubist Pharmaceuticals, Inc. | Tazobactam arginine antibiotic compositions |
CN105025901B (zh) * | 2012-09-27 | 2019-04-19 | 默沙东公司 | 他唑巴坦精氨酸抗生素组合物 |
AU2018203806B2 (en) * | 2012-09-27 | 2020-04-02 | Merck Sharp & Dohme Llc | Tazobactam arginine antibiotic compositions |
US9320740B2 (en) | 2013-03-15 | 2016-04-26 | Merck Sharp & Dohme Corp. | Ceftolozane-tazobactam pharmaceutical compositions |
US9925196B2 (en) | 2013-03-15 | 2018-03-27 | Merck Sharp & Dohme Corp. | Ceftolozane-tazobactam pharmaceutical compositions |
US10376496B2 (en) | 2013-09-09 | 2019-08-13 | Merck, Sharp & Dohme Corp. | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
US10933053B2 (en) | 2013-09-09 | 2021-03-02 | Merck Sharp & Dohme Corp. | Treating infections with ceftolozane/tazobactam in subjects having impaired renal function |
Also Published As
Publication number | Publication date |
---|---|
CN1109688C (zh) | 2003-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Clarke | Chemistry of penicillin | |
Turel et al. | Interactions of oxovanadium (IV) and the quinolone family member—ciprofloxacin | |
Miodragović et al. | Interesting coordination abilities of antiulcer drug famotidine and antimicrobial activity of drug and its cobalt (III) complex | |
Durig et al. | The induction of filamentous growth in Escherichia coli by ruthenium and palladium complexes | |
CN1109688C (zh) | 他唑巴坦半水合物的制备与应用 | |
CN103524532B (zh) | 一种头孢唑肟钠化合物晶型、制备方法及其药物制剂 | |
Gungor et al. | Cu (II) complexes of biguanidine ligands: Structural characterisation, DNA binding and antimicrobial properties | |
CN105853441A (zh) | 一种头孢哌酮钠舒巴坦钠组合物 | |
CN107325096B (zh) | 一种阿维巴坦单钠盐的结晶 | |
Riddles et al. | Synthesis and characterization of two cyanoxime ligands, their precursors, and light insensitive antimicrobial silver (I) cyanoximates | |
Yano et al. | Antifungal nickel (II) complexes derived from amino sugars against pathogenic yeast, Candida albicans | |
Sultana et al. | Synthesis and antibacterial activity of cephradine metal complexes: part I complexes with magnesium, calcium, chromium and manganese | |
CN100484526C (zh) | 一种硫酸头孢匹罗原料的合成方法及其用途 | |
Litvin et al. | Quercetin as a precursor in the synthesis of analogues of fulvicacids and their antibacterial properties | |
CN105646539B (zh) | 一种减少过敏反应的头孢替安盐酸盐及其制剂 | |
Jamil et al. | Ligational and spectroscopic on some sulfamethoxazole metal complexes as antimicrobial agents | |
Mihalache et al. | Synthesis, characterization, and biological activity of some complex combinations of nickel with α-ketoglutaric acid and 1-(o-tolyl) biguanide | |
Isab et al. | Synthesis and characterization of thiolate–Ag (I) complexes by solid-state and solution NMR and their antimicrobial activity | |
Bergs et al. | Preparation and characterization of the heptachlorobis (tetrahydrofuran) ditungstate and octachloro (tetrahydrofuran) ditungstate anions:[Ph4P][W2Cl7 (THF) 2] and [Ph4P][W2Cl8 (THF)] | |
Kong et al. | Synthesis, stability and structural characterization of a new macrocyclic ligand with four neutral pendent groups: 1, 4, 7, 10-tetrakisbenzyl-1, 4, 7, 10-tetraazacyclo dodecane (L) and its Co and Cu complexes | |
Agnes et al. | Metal-binding cyclodextrins: Synthesis and complexation with Zn2+ and Ga3+ cations towards antimicrobial applications | |
CN1315846C (zh) | 7 -{ [ ( 5 -氨基 - 1 , 2 , 4 -噻二唑 - 3 -基 ) (氟代甲氧基亚氨基 )乙酰基 ]氨基} - 3 - [ (亚氨基 - 1-哌嗪基甲基 ) -甲基亚肼基 ] -甲基 -3 -头孢烯 - 4 -羧酸的结晶盐酸化物 | |
Costa et al. | Key Parameters on the Antibacterial Activity of Silver Camphor Complexes. Antibiotics 2021, 10, 135 | |
Drouza et al. | Synthesis and aqueous solution properties of multinuclear oxo-bridged vanadium (IV/V) complexes | |
CN109160932A (zh) | 一种11/2水胞磷胆碱钠化合物及其药物组合物制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Qian Baoying Document name: Special business review memo |
|
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Hainan general SANYO Pharmaceutical Co., Ltd. Assignor: National Institute for the Control of Pharmaceutical and Biological Products Contract fulfillment period: 2009.9.21 to 2015.9.21 Contract record no.: 2009460000017 Denomination of invention: Preparation and application of tazobactam semihydrate Granted publication date: 20030528 License type: Exclusive license Record date: 20091013 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2009.9.21 TO 2015.9.21; CHANGE OF CONTRACT Name of requester: HAINAN PROVINCE GENER-SANYANG MEDICINE CO., LTD. Effective date: 20091013 |
|
ASS | Succession or assignment of patent right |
Owner name: HAINAN GENERAL SANYO PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: NATIONAL INSTITUTE FOR THE CONTROL OF PHARMACEUTICAL AND BIOLOGICAL PRODUCTS Effective date: 20091225 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20091225 Address after: Hainan province Haikou City Xiuying Yong GUI Industrial Zone Patentee after: Hainan General Sanyang Pharmaceutical Co., Ltd. Address before: No. 2, West Lane, Tiantan, Beijing Patentee before: National Institute for the Control of Pharmaceutical and Biological Products |
|
CP02 | Change in the address of a patent holder |
Address after: 570312 Hainan Province, Haikou City Xiuying District No. 8 Haililu Patentee after: Hainan General Sanyang Pharmaceutical Co., Ltd. Address before: 570312 Hainan province Haikou City Xiuying Yong GUI Industrial Zone Patentee before: Hainan General Sanyang Pharmaceutical Co., Ltd. |
|
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Hainan general SANYO Pharmaceutical Co., Ltd. Assignor: National Institute for the Control of Pharmaceutical and Biological Products Contract record no.: 2009460000017 Date of cancellation: 20110504 |
|
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Jingdezhen Fuxiang Pharmaceutical Co., Ltd. Assignor: Hainan General Sanyang Pharmaceutical Co., Ltd. Contract record no.: 2011360000023 Denomination of invention: Preparation and application of tazobactam semihydrate Granted publication date: 20030528 License type: Exclusive License Open date: 19991201 Record date: 20110509 |
|
EM01 | Change of recordation of patent licensing contract |
Change date: 20121010 Contract record no.: 2011360000023 Assignee after: Jingdezhen Fuxiang Pharmaceutical Co., Ltd. Assignee before: Jingdezhen Fuxiang Pharmaceutical Co., Ltd. |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Jingdezhen Fuxiang Pharmaceutical Co., Ltd. Assignor: Hainan General Sanyang Pharmaceutical Co., Ltd. Contract record no.: 2011360000023 Date of cancellation: 20140417 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20030528 |